MEDVi QUAD vs BlueChew Gold: QUAD Just Changed Its Formula, and the Comparison Changed With It

Until recently these two products were near-twins — three shared ingredients and one point of difference. On July 16, 2026, MEDVi reformulated QUAD and that stopped being true. QUAD dropped two ingredients and added two others. BlueChew Gold stayed exactly where it was. Here's what each formula now contains and what the research actually supports.

What actually changed in QUAD

Both products still share the same foundation: sildenafil for fast blood flow and tadalafil for the long window. That part is unchanged and it's the part doing most of the heavy lifting in either product. The difference is in the two ingredients each one builds on top of that base.

QUAD used to add a third PDE5 inhibitor (vardenafil) plus apomorphine. Both are gone. In their place MEDVi added L-citrulline and PT-141 — which is a genuine change in strategy, not a relabel. The old formula stacked a third drug onto the same blood-flow mechanism. The new one keeps two PDE5 inhibitors and spends its remaining two slots on a different problem: supporting the nitric oxide those drugs depend on, and addressing desire directly.

MEDVi's stated reasons for the change are taste and approval rates — they say the reformulated product is easier to take and improves a patient's chance of being approved at consultation. Whether the new formula outperforms the old one for any given man is not something anyone has published data on yet, and we're not going to pretend otherwise.

L-citrulline: modest evidence, sensible logic

L-citrulline is an amino acid your body converts into L-arginine, which raises nitric oxide production. Nitric oxide is what relaxes blood vessels — and it's the exact pathway sildenafil and tadalafil act on. PDE5 inhibitors don't create nitric oxide; they preserve its downstream signal. So supplying more of the raw material is a coherent thing to pair them with.

The clinical evidence is real but modest. A small single-blind study published in Urology in 2011 followed 24 men with mild ED and found that 50% reported improved erection hardness on oral L-citrulline, compared with 8% on placebo. That's a genuine positive result, and it's also 24 men in mild cases. L-citrulline is a supplement-grade amino acid, not an FDA-approved ED drug, and it should be read as a supporting ingredient rather than a primary treatment.

PT-141: the ingredient that makes this comparison interesting

PT-141, also known as bremelanotide, is the more consequential addition. It's a melanocortin receptor agonist, which means it acts on arousal pathways in the brain rather than on blood vessels. It targets wanting sex, not the mechanics of an erection — a genuinely different target from everything else in either product.

It's FDA-approved as Vyleesi, prescribed since 2019 for hypoactive sexual desire disorder in premenopausal women, delivered by injection. In men, early-phase trials of intranasal bremelanotide showed erectogenic effects, including in some men who hadn't responded to sildenafil. That development program was never carried through to approval for ED, partly over blood-pressure concerns. So its inclusion in a compounded formula is off-label and prescriber-supervised.

We want to be precise about what that means, because the honest version is more useful than the marketing version: PT-141 is not FDA-approved for erectile dysfunction. What it does have is an FDA approval in a related sexual-function indication and published human trial data in men. That's a meaningfully better evidence base than the desire ingredient sitting in BlueChew Gold.

Oxytocin: the case falls apart quickly

Oxytocin is a neuropeptide primarily known for its role in social bonding, trust, and maternal behavior. BlueChew markets it as supporting "emotional connection" and "deeper intimacy." That language is doing a lot of heavy lifting, because the clinical reality is less compelling.

Problem 1: No ED evidence. Oxytocin has never been approved for treating erectile dysfunction. There are no published randomized controlled trials showing that oxytocin improves erection quality, firmness, or reliability. Some early-stage research explores oxytocin's role in sexual behavior broadly, but there's a wide gap between "may play a role in sexual behavior" and "treats erectile dysfunction."

Problem 2: It barely absorbs sublingually. This is the bigger issue. Published research puts sublingual oxytocin bioavailability at approximately 4.5%, with "10-fold variation" between individuals. The researchers explicitly concluded that sublingual delivery "would not seem a reliable route" for administering oxytocin therapeutically. Even intranasal delivery — the standard research method — only achieves 11% bioavailability.

So you have an ingredient that isn't proven for ED, and even if it were, the delivery method used by BlueChew Gold fails to get meaningful amounts into the bloodstream. That's a rough combination.

The apomorphine split

One consequence of the reformulation is worth stating plainly, because it cuts both ways. QUAD no longer contains apomorphine. BlueChew Gold and Rugiet Ready both still do.

Apomorphine is a dopamine agonist that's also used in Parkinson's disease treatment, a dual use that drew media attention earlier in 2026 when QUAD's original four-drug formula was covered in the trade press. MEDVi hasn't tied the removal to that coverage — their stated reasons are taste and approval rates. We're not going to speculate about motive, and we're not going to imply that apomorphine in BlueChew Gold is unsafe, because that's not what the evidence says.

What we can say factually: if apomorphine is an ingredient you'd rather avoid, QUAD is now the only one of these three products without it. If you've used apomorphine-containing products successfully and want to keep it, BlueChew Gold and Rugiet Ready still have it and QUAD no longer does. Same fact, opposite conclusions, depending on where you sit.

Format: liquid vs dissolving tablet

QUAD uses a sublingual liquid. BlueChew Gold uses a rapidly dissolving tablet (RDT) that you place under or on your tongue.

Both approaches skip the digestive system, which is the primary advantage over swallowed pills. But there's a practical difference in absorption consistency. With a liquid, the active ingredients are already dissolved — absorption begins the moment the liquid contacts the sublingual membrane. With a dissolving tablet, the drug first needs to dissolve in your saliva before absorption can begin. BlueChew Gold's RDT dissolves quickly, but there's been user feedback about chalky texture and inconsistent dissolution.

There's also the blue tongue issue. Multiple BlueChew Gold reviews mention that the tablet leaves a visible blue residue on the tongue — not exactly subtle if you're trying to be discreet about taking it. QUAD's liquid doesn't have this problem.

Neither product has Rugiet Ready's melting problem (since neither is a solid troche that needs refrigeration), so both are fine for portability.

Pricing: BlueChew Gold wins on cost, QUAD wins on value

Let's not dance around it: BlueChew Gold is cheaper. Significantly cheaper.

If budget is your primary constraint, BlueChew Gold is the more affordable option. There's no getting around that, and the reformulation didn't change it.

The value question is different from the price question. You're paying roughly $52 more per month for QUAD. What that buys you is a different second half of the formula: L-citrulline supporting the nitric oxide pathway, and PT-141 targeting desire with an evidence base that oxytocin doesn't have. It does not buy you a third PDE5 inhibitor anymore — that was the old formula's pitch, and it's gone.

So the honest framing is this. If your problem is primarily mechanical — you need firmer, more reliable erections and nothing else — the shared sildenafil-plus-tadalafil base is doing that work in both products, and BlueChew Gold delivers it for $52 less. If your problem includes low desire, QUAD's PT-141 is the only ingredient across either product with meaningful human data behind it for that specific complaint. That's what the premium is actually for now.

BlueChew also has the weight of brand recognition behind it — over 4 million users across their product line. That matters for some men. Brand familiarity doesn't change the pharmacology, but it does change the comfort level of trying something new.

What BlueChew Gold does well

Credit where it's due. BlueChew Gold isn't a bad product. Its three evidence-backed ingredients — sildenafil, tadalafil, apomorphine — are a proven foundation, and for most men they'll produce meaningful improvement in erectile function. The product is affordable, accessible through a massive telehealth platform, and comes from a brand that millions of men already trust.

It's also worth noting that BlueChew Gold now keeps something QUAD gave up. Apomorphine has clinical evidence behind it for ED, and QUAD removed it in July. If you've used apomorphine-containing products and done well on them, BlueChew Gold and Rugiet Ready still offer that and QUAD doesn't. That's a real point in Gold's favor, not a consolation prize.

The weak spot remains oxytocin. BlueChew positions Gold as a four-ingredient product, but the fourth ingredient doesn't have the evidence or the absorption to contribute much. That was true before QUAD reformulated and it's still true now.

Who should choose which

Our verdict

The July reformulation made this a closer call than it used to be, and in a more interesting way. These are no longer two versions of the same product separated by one ingredient. They're two different bets.

BlueChew Gold bets on the established combination and a lower price: two PDE5 inhibitors plus apomorphine, all with ED evidence behind them, for around $67 a month. The oxytocin is filler, but you're not really paying for it.

QUAD bets on covering a second pathway. It keeps the same PDE5 base, supports it with L-citrulline, and spends its last slot on PT-141 — the one ingredient in this comparison with published human data for desire specifically, and an FDA approval in a related indication. It costs more and it's less established in this exact combination.

So: if your problem is purely getting and keeping an erection, the shared base does that in both products and BlueChew Gold does it for less money. If desire is part of the picture, QUAD is the only one of the two making a serious, evidence-backed attempt at it. That's the decision now — not which product has more proven ingredients, but which pathway you actually need treated.

Frequently Asked Questions

More Comparisons